Skip to main content
The NCI Community Hub will be retiring in May 2024. For more information please visit the NCIHub Retirement Page:https://ncihub.cancer.gov/groups/ncihubshutdown/overview
close

NCL Method ITA-18

By Timothy Potter, Barry Neun, Sarah Skoczen, Anna Ilinskaya, Marina Dobrovolskaia

Human Leukocyte Proliferation Assay (HuLa)

Listed in Datasets | publication by group NCL Protocols

Version 1.0 - published on 04 May 2020 doi:10.17917/C59D-T717 - cite this Last public release: 2.0b

Licensed under these terms

Description

Immunosuppression is a common reason for drug withdrawal from the market. Traditional immune function tests used to estimate a material’s immunosuppression is T-cell dependent antibody response (TDAR). This method involves a 28 day in vivo study evaluating an animal’s antibody titer to a known antigen (KLH) with and without challenge. Due to the limited quantities of novel drug candidates, an in vitro method called Human Leukocyte activation (HuLa) has been developed as a substitute for the traditional TDAR assay during early preclinical evaluation. The method presented herein is based on the HuLa assay originally developed by Mark Collinge, et al at Pfizer [1]. The protocol presented in this document has been adapted for use with engineered nanomaterials.

Content List

Cite this work

Researchers should cite this work as follows:

Tags

Recommendations

Powered by ...

NCL Protocols

NCL Protocols group image

When watching a publication, you will be notified when a new version is released.